Universe Pharmaceuticals INC (UPC)
↓ Download CSV- Sector Manufacturing
- Incorporated F4
- Fiscal year ends Sep 30
In fiscal 2025, Universe Pharmaceuticals INC reported revenue of $17.86B, down 22.4% from the prior year. The company ran a net loss, with a net margin of -20.6% and a gross margin of 35.3%. It held $69.30B in total assets against $13.17B in total liabilities.
Key ratios (FY2025)
35.3%
Gross margin
-16.3%
Operating margin
-20.6%
Net margin
-6.5%
Return on equity
-22.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.86B | $23.02B | $32.31B | $40.14M | $47.98M | $30.70M | $33.23M | — |
| Cost of Revenue | $11.56B | $16.95B | $21.99B | $18.25M | $22.66M | $16.61M | $19.82M | — |
| Gross Profit | $6.30B | $6.07B | $10.32B | $21.89M | $25.33M | $14.09M | $13.41M | — |
| Operating Income | -$2.92B | -$8.02B | -$3.97B | -$7.02M | $13.59M | $10.25M | $9.75M | — |
| Net Income | -$3.67B | -$8.73B | -$6.58B | -$7.91M | $11.32M | $7.56M | — | — |
| EPS (Diluted) | $-8.06 | $-626.96 | $-1089.21 | $-1309.11 | $3.58 | $0.47 | — | — |
| Total Assets | $69.30B | $67.95B | $41.72M | $59.54M | $70.14M | $28.80M | — | — |
| Total Liabilities | $13.17B | $22.45B | $13.75M | — | — | — | — | — |
| Shareholders' Equity | $56.13B | $45.50B | $27.97B | $35.33B | $46.99M | $20.80M | $12.38M | $9.68M |
| Cash & Equivalents | — | — | — | — | $8.08M | $10.06M | $3.18M | $6.19M |
| Operating Cash Flow | -$5.05B | -$9.51B | $1.12B | -$1.30M | -$2.06M | $6.12M | $13.20M | — |
| Capital Expenditures | $266.77M | $208.32M | $44.17M | $93.7K | $444.5K | $51.8K | $86.3K | — |
| Shares Outstanding | 563.3K | 42.9K | 6.1K | 3.62M | 21.75M | 16.00M | — | — |